Immunome Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Revenue	14.02	0	0	0	0	0
Gross Profit	14.02	0	0	0	0	0
Selling, General & Admin	19.66	13.63	11.09	4.78	1.53	0.87
Research & Development	23.09	23.27	14.11	7.49	8.82	6.88
Other Operating Expenses	80.8	0	0	0	0	0
Operating Expenses	123.55	36.9	25.2	12.26	10.35	7.74
Operating Income	-109.53	-36.9	-25.2	-12.26	-10.35	-7.74
Interest Expense / Income	0	0	0.01	0.04	0.1	0.1
Other Expense / Income	-2.72	-0.01	-0.5	5.54	-	-
Pretax Income	-106.81	-36.9	-24.71	-17.84	-10.44	-7.85
Net Income	-106.81	-36.9	-24.71	-17.84	-10.44	-7.85
Preferred Dividends	0	0.62	0	0	0	0
Net Income Common	-106.81	-37.52	-24.71	-17.84	-10.44	-7.85
Shares Outstanding (Basic)	20	12	12	3	1	7
Shares Outstanding (Diluted)	20	12	12	3	1	7
Shares Change	63.64%	5.10%	240.41%	209.85%	-83.22%	-
EPS (Basic)	-5.38	-3.09	-2.14	-5.26	-9.55	-1.20
EPS (Diluted)	-5.38	-3.09	-2.14	-5.26	-9.55	-1.20
Free Cash Flow	-8.4	-28.94	-18.31	-12.72	-9.83	-7.63
Free Cash Flow Per Share	-0.42	-2.39	-1.59	-3.75	-8.99	-1.17
Gross Margin	100.00%	-	-	-	-	-
Operating Margin	-781.35%	-	-	-	-	-
Profit Margin	-761.92%	-	-	-	-	-
Free Cash Flow Margin	-59.92%	-	-	-	-	-
EBITDA	-106.08	-36.27	-23.95	-17.04	-9.73	-7.22
EBITDA Margin	-756.73%	-	-	-	-	-
Depreciation & Amortization	0.73	0.63	0.76	0.76	0.62	0.52
EBIT	-106.81	-36.9	-24.7	-17.8	-10.35	-7.74
EBIT Margin	-761.92%	-	-	-	-	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).